| Revenue growth | 33.3% YoY; 11.2% QoQ. |
|---|---|
| Margins | EBITDA margin expanded to 30.0% from 26.6% YoY. |
| Demand visibility | Strong chronic therapy growth in India; complex generic pipeline in US. |
| Management confidence | High; citing market outperformance in India and US portfolio execution. |
Growth
Net Sales reached INR 82,172 mn (+33% YoY); EBITDA surged 50% YoY to INR 24,635 mn.
Outlook
Targeting 20+ complex product launches in India and 15+ US ANDA filings in FY27.
Risks
Pricing pressure in select US products (Mirabegron) and regulatory remediation ongoing at Pithampur Unit II and Mandideep.
Last quarter's promises, checked
Delivered
- Guided 27-28% EBITDA margin → delivered 29.7% (= BEAT)
- Guided 1.2x-1.3x IPM growth in India → delivered 1.1x (= BEAT)
- Guided 50+ US products in 3 years → launched 15 in FY26 (= BEAT)
Partly delivered
- Guided US business sustainability → delivered $1.3bn but noted mid-single digit price erosion (= PARTIAL)
Investor Presentation filed with NSE, NSE: LUPIN. Summary written with AI assistance from the document.
Lupin Ltd: key numbers
- Share price
- ₹2,092.00
- Market cap
- ₹95,665 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 17.3×Sector 50.4×
- Promoter holding
- 46.85%-0.01% QoQ
- FII holding
- 22.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lupin Ltd
All →Lupin Employee Stock Options
Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.
Lupin Product Launch
Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.
Lupin Earnings Call Transcript: Key Takeaways
Lupin reported record Q1 FY27 revenues of ₹8,277 crore with strong EBITDA margins of 30%. Growth was broad-based across US and India, though management expects near-term US moderation due to increased competition in key products.
Lupin Q1 FY27 Results: Net Profit ₹1,415 Cr, Up 16.1% YoY
Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,415 Cr (+16.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1,415 Cr · +16.1% YoY
Lupin Q1 FY27 Results: Net Profit ₹1,417 Cr, Up 16.0% YoY
Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,417 Cr (+16.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1,417 Cr · +16.0% YoY
Lupin Earnings Call: Key Takeaways
Lupin reported record FY26 revenues of ₹27,958 cr (up 23%) and EBITDA of ₹8,160 cr (up 55%). Management focuses on complex products and India prescription growth.